Home › Compare › HBGRF vs ABBV
HBGRF yields 116.96% · ABBV yields 3.06%● Live data
📍 HBGRF pulled ahead of the other in Year 1
Combined, HBGRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HBGRF + ABBV for your $10,000?
Heidelberger Druckmaschinen Aktiengesellschaft, together with its subsidiaries, manufactures, sells, and deals in printing press and other print media industry products in Europe, the Middle East, Africa, Asia/Pacific, Eastern Europe, North America, and South America. The company operates through Print Solutions, Packaging Solutions, and Technology Solutions segments. It offers printing machines, including digital, offset, narrow web, screen, and inline-flexo printing, as well as remarketed equipment; and finishing equipment comprising cutting, die-cutting and embossing, folding, inspection, folding carton gluing, hot foil stamping, and shingled folding. The company also provides technical services, such as installation and relocation, maintenance and cleaning, remote support, repair, and overhauling services, as well as service parts; and performance services consisting of performance evaluation, color management, training, upgrades and retrofits, monitoring, output optimization, print shop optimization, and investment planning. In addition, it offers financial services; and consumables, such as plates, films, chemicals, proofing, glues, digital and analog engraving, blankets, inks, dampening rollers, coatings, varnishes, blankets, rollers, pressroom chemicals, cutting knives, banderoles, ink duct foils, wash-up cloths and spray powders, dispersion glues, binding glues, stitching wires and sealing threads, and folding carton gluing supplies. Further, the company provides software solutions. The company was formerly known as Schnellpressenfabrik AG Heidelberg and changed its name to Heidelberger Druckmaschinen Aktiengesellschaft in 1967. Heidelberger Druckmaschinen Aktiengesellschaft was founded in 1850 and is based in Heidelberg, Germany.
Full HBGRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.